1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process after Acceptance
8. Post Publication
9. Editorial Office Contact Details

 

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/medcomm-futmed 

Click here for more details on how to use ScholarOne.

Data protection:

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

Preprint policy:

Please find the Wiley preprint policy here.

This journal considers article previously published on preprint servers.

MedComm - Future Medicine will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication.

For help with submissions, please contact: [email protected].

2. AIMS AND SCOPE

MedComm – Future Medicine is a peer-reviewed，open access journal that publishes high quality research in medicine and biology on the basis of novelty, timeliness and significance to human health and diseases. It covers the latest advances in biomedical research and healthcare delivery that will address unmet medical needs and transform future medical therapies. These include demonstration of technological innovations (including screening, diagnosis, prevention and treatment) and novel interventions for human diseases with potential for future clinical translation.
MedComm – Future Medicine is a multidisciplinary journal covering topics of interest, including multiomics, bioinformatics, medical artificial intelligence (AI), stem cell and regenerative medicine, gene editing and therapy, relating to major human health and diseases, including but not limited to cancer, cardiovascular diseases, autoimmune diseases, nervous system diseases, and aging.
MedComm – Future Medicine focuses on the discovery of novel disease mechanisms and application of cutting-edge technologies to meet medical challenges. Relevant topics include, but are not limited to, development of ground-breaking technologies and therapies, interdisciplinary approaches, application of big data and AI in healthcare delivery, and precision medicine for early detection and outcome prediction for major diseases.

 

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

• Original article is the full-length report of current research within any area covered in the journal’s scope, and aims to address novel findings and make significant contribution to the scientific knowledge in application of cutting-edge techniques areas. Typically, the research will provide insight into an as yet unknown mechanism or poorly understood process, constitute a highly significant contribution to our understanding of biomedicine, and be of general interest to the biomedicine community. Research article will typically be 6000 words in length, with up to 8 figures and tables in total, and no limitation on the number of references.
• Review is the systematic review, typically written by leading experts in the filed within the journal’s scope. Reviews papers help specialists to keep up with the current state of knowledge in a specific research area and provide informative message for non-specialists. Reviews aim to be a critical and concise overview of the most recent advances in a specific research field. Reviews will typically be no limitation on words in length, with up to 8 figures and tables in total, and no limitation on the number of references.
• Letter provides the rapid and concise report of a novel discovery that is brief in nature and should be of general interest to the field of cutting-edge techniques in biomedicine. Letters will typically be 1200 words in length excluding, references, figures and tables, with no more than one display item, and no more than 5 references.
• Highlight aims to point the MedComm - Future Medicine readership to the latest novel findings published in other high-impact journals. Research Highlight should contain no more than 1200 words in length excluding, references, figures and tables, up to 10 references and 1 display item.
• Editorials are the most important statement and opinions of global opinion leaders in relevant specialties and specially invited by the Editor, but unsolicited material may be considered. Please approach the Editorial Office ([email protected]) before submitting this material. Editorials have a limit of 1,000 words, with up to 2 figures and tables in total and no more than 5 references.
• Perspectives discuss published findings and ideas from a personal viewpoint. They are more forward looking and /or speculative than Reviews. Perspectives can be submitted either by the invitations from the Editors or by the authors themselves. Both types will undergo the peer-review process prior to acceptance.  Perspectives are typically 3000 words in length, with up to 4 figures and tables in total and no more than 70 references.

4. PREPARING THE SUBMISSION

Cover Letters

Cover letters are not mandatory; however, they may be supplied at the author’s discretion.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

1. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
2. A short running title of less than 40 characters;
3. The full names of the authors;
4. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
5. Acknowledgments, Author Contributions, Conflicts of Interests, Ethics Statement, Data Availability Statement;
6. Abstract and keywords;
7. Main text;
8. References;
9. Tables (each table complete with title and footnotes);
10. Figure legends;
11. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

For the benefit of the reviewers and editors, please include line numbers in your main text files.

Abstract

Please provide an abstract of no more than 250 words containing the major keywords summarizing the article.

Keywords

Please provide three to six keywords.

Main Text

• The journal uses British/US spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process.
• Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter

Methods and Materials

If a method or tool is introduced in the study, including software, questionnaires, and scales, the author should state the license this is available under and any requirement for permission for use. If an existing method or tool is used in the research, the authors are responsible for checking the license and obtaining the permission. If permission was required, a statement confirming permission should be included in the Methods and Materials section.

References

References should follow the AMA style, meaning all references should be numbered consecutively in order of appearance and should be as complete as possible. In-text citations should cite references in consecutive order using Arabic superscript numerals. For more information about AMA reference style please see the AMA Manual of Style. Sample references follow:

Journal article

1. Pan Q, Qin T, Gao Y, et al. Hepatic mTOR‐AKT2‐Insig2 signaling pathway contributes to the improvement of hepatic steatosis after Roux‐en-Y Gastric Bypass in mice. Biochim Biophys Acta Mol Basis Dis. 2019;1865(3):525‐534. 

Journal article with no named author or group name

2. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use--Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):273.

Book Chapter

3. Guyton JL, Crockarell JR. Fractures of acetabulum and pelvis. In: Canale ST, ed.Campbell's Operative Orthopaedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003:2939-2984.

Electronic Book

4. Rudolph CD, Rudolph AM. Rudolph's Pediatrics. 21st ed. New York, NY: McGraw-Hill Companies; 2002. http://online.statref.com/Document/Document.aspx?DocID=1&StartDoc=1&EndDoc=1882&FxID=13&offset=7&SessionId=A3F279FQVVFXFSXQ . Accessed August 22, 2007.

Footnotes

Footnotes should be placed as a list at the end of the paper only, not at the foot of each page. They should be numbered in the list and referred to in the text with consecutive, superscript Arabic numerals. Keep footnotes brief; they should contain only short comments tangential to the main argument of the paper and should not include references.

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for p-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Color figures. Figures submitted in color may be reproduced in color online free of charge.

Data Citation

Please review Wiley’s data citation policy here.

Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Graphical Abstracts

MedComm - Future Medicine publishes graphical abstracts for research articles and review articles, displayed online in graphical form with a brief abstract, in addition to the up to 250 word abstract above. The online table of contents will display a schematic figure to convey the core message of your paper, alongside a short abstract highlighting the major findings of the paper. Authors should submit a new and stand-alone image, or designate an image already included in the paper. Your short abstract should consist of 2-3 sentences summarizing the essence of the paper. Graphical abstract entries should be submitted to ScholarOne in one of the generic file formats and uploaded as ‘Graphical Abstract’ during the initial manuscript submission process. The image should fit within the dimensions of 50mm x 60mm, and be fully legible at this size.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

Authorship and Author Contribution

All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version.

The contributions of all authors must be described. The contribution statement will be published with the final article and should accurately reflect contributions to the work. MedComm - Future Medicine has adopted the CRediT taxonomy of author contributions. The CRediT contribution terms are as follows: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, writing - original draft, and writing - review and editing. For full details of the CRediT taxonomy and the scope of each term, please consult CRediT Taxonomy.

Sample Author Contribution Section

Author Contributions:

John Smith: Conceptualization, formal analysis, funding acquisition, software, and writing – review and editing.

Sarah Jones: Data curation, methodology, project administration, writing – original draft, and writing – review and editing.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed by two reviewers. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

In-house submissions, i.e. papers authored by Editors or Editorial Board members of the title, will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias.

Wiley's policy on the confidentiality of the review process is available here.

Guidelines on Publishing and Research Ethics in Journal Articles

The journal requires that you include in the manuscript details IRB approvals, ethical treatment of human and animal research participants, and gathering of informed consent, as appropriate. You will be expected to declare all conflicts of interest, or none, on submission. Please review Wiley’s policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines.

This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices).

This journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors and Wiley’s Publication Ethics Guidelines.

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.  

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

• DNA Data Bank of Japan (DDBJ): www.ddbj.nig.ac.jp
• EMBL Nucleotide Archive: ebi.ac.uk/ena
• GenBank: www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories:

• Protein Information Resource (PIR): pir.georgetown.edu
• SWISS-PROT: expasy.ch/sprot/sprot-top

Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). Please note that the data in databanks must be released, at the latest, upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

• Organic and organometallic compounds: Crystallographic data should not be sent as Supporting Information, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) at ccdc.cam.ac.uk/services/structure%5Fdeposit.
• Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; fiz-karlsruhe.de).
• Proteins and nucleic acids: Protein Data Bank (rcsb.org/pdb).
• NMR spectroscopy data: BioMagResBank (bmrb.wisc.edu).

Data Sharing and Data Accessibility

Please review Wiley’s policy here.  This journal encourages data sharing.

The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

All accepted manuscripts may elect to publish a data availability statement to confirm the presence or absence of shared data. If you have shared data, this statement will describe how the data can be accessed, and include a persistent identifier (e.g., a DOI for the data, or an accession number) from the repository where you shared the data.

Sample statements are available here.  If published, statements will be placed in the heading of your manuscript.

Human subject information in databases. The journal refers to the World Health Medical Association Declaration of Taipei on Ethical Considerations Regarding Health Databases and Biobanks.

ORCID

Please see Wiley’s resources on ORCID here.

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal encourages the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.

6. AUTHOR LICENSING

All articles published by MedComm - Future Medicine are fully open access where they are immediately freely available to read, download and share. To cover the cost of publishing, MedComm - Future Medicine charges a publication fee when a submission is accepted for publication. There is no fee for initial submission for editorial/peer-review evaluation. Accepted papers will be published under CC BY - Creative Commons Attribution License. With the Creative Commons license, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and to identify as the original publisher.

If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.

To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here.

Open Access fees: Please note: Article Publication Charges (APCs) are currently waived. For more information on this journal’s APCs, please see the Open Access page.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Article Received in Production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Proofs

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. The Online Proofing System is supported by all major browsers, such as Edge, Chrome, Firefox, Safari, and Opera; however Chrome is highly recommended. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned as soon as possible from receipt of the email. Return of proofs via e-mail is possible in the event that the online system cannot be used or accessed.

Citing this Article: eLocators

This journal now uses eLocators. eLocators are unique identifies for an article that service the same function page numbers have traditionally served in the print world. When citing this article, please insert the eLocator in place of the page number. For more information, please visit the Author Services eLocator page here.

8. POST PUBLICATION

Access and Sharing

Please review Wiley’s guidelines on sharing your research here. The submitted version of the manuscript, the accepted version, and the published version (Version of Record) can all be deposited on an institutional or other repository of the author's choice without embargo.

When the article is published online:

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.

Promoting the Article

To find out how to best promote an article, click here.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

Archiving Services

Portico and CLOCKSS are digital archiving/preservation services we use to ensure that Wiley content will be accessible to customers in the event of a catastrophic event such as Wiley going out of business or the platform not being accessible for a significant period of time.  Member libraries participating in these services will be able to access content after such an event. Wiley has licenses with both Portico and CLOCKSS, and all journal content gets delivered to both services as it is published on Wiley Online Library.  Depending on their integration mechanisms, and volume loads, there is always a delay between content being delivered and showing as “preserved” in these products.

9. EDITORIAL OFFICE CONTACT DETAILS

EDITORIAL CONTACT

MedComm - Future Medicine Editorial Office

Email: eidtorial@mc-futmed.org

No.1103-1105, Building 6, S2, Global Center, High-tech Zone

Chengdu, China

Tel: 028-80592559-8002

 

Author Guidelines updated 19 January 2022